BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis-Reference-Cited by-同舟云学术

BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis

Published:2011-05-04 Issue:12 Volume:50 Page:2311-2313
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:Rheumatology

Author:

Bukhari M.,Abernethy R.,Deighton C.,Ding T.,Hyrich K.,Lunt M.,Luqmani R.,Kiely P.,Bosworth A.,Ledingham J.,Ostor A.,Gadsby K.,McKenna F.,Finney D.,Dixey J.,

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/50/12/2311/5061418/ker106a.pdf

Reference4 articles.

1. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy

2. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

3. Consensus statement on the use of rituximab in patients with rheumatoid arthritis

4. Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Principles of Systemic Therapy;Rook's Textbook of Dermatology;2024-02-20

2. Salivary IgA subtypes as novel disease biomarkers in systemic lupus erythematosus;Frontiers in Immunology;2023-02-22

3. Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment;Frontiers in Immunology;2022-12-22

4. Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees;Journal of Allergy and Clinical Immunology;2022-05

5. Rituximab exhibits a better safety profile when used as a first line of treatment for pemphigus vulgaris: A retrospective study;International Immunopharmacology;2021-07